Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Actavis Laboratories FL, Inc.
WARNING LETTER
•Actavis Laboratories FL, Inc.•July 19, 2018

Actavis Laboratories FL, Inc. – FDA Warning Letter, Jul 19, 2018

Record Details

The FDA inspected Actavis Laboratories FL, Inc. from July 9 to 19, 2018, identifying significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211), rendering their drug products adulterated under section 501(a)(2)(B) of the FD&C Act. The firm failed to establish adequate written procedures for production and process control (21 CFR 211.100(a)), particularly for laser-drilled tablet manufacturing, which lacked sufficient design, validation of critical parameters, and evaluation of visual inspection system changes. Additionally, Actavis failed to establish control procedures to monitor output and validate manufacturing processes (21 CFR 211.110(a)), including inadequate operator qualification for in-process checks and AQL inspections, and insufficient procedures, lighting, and equipment. The Quality Control Unit was deemed inadequate (21 CFR 211.22(a)), failing to provide robust oversight of the laser drilling process, validation, change management, equipment maintenance, training, and timely investigations, leading to voluntary recalls. Finally, the firm failed to thoroughly investigate unexplained discrepancies or batch failures (21 CFR 211.192), exhibiting inadequate root cause analyses and ineffective corrective and preventive actions for drug product defects. These are repeat observations, indicating inadequate executive management oversight. Actavis must promptly correct all violations, respond within 15 working days, and address potential drug supply disruptions. Failure to comply may result in legal action, withholding of drug application approvals, and refusal of export certificates.

Company
Actavis Laboratories FL, Inc.
Inspection date
July 19, 2018
Product type
Drugs
Office
Dallas District Office
People
  • Monica R. Maxwell (Program Division Director)
  • Sergio Vella
  • Kare Schultz
  • Renee Alsobrook
View Company Profile

ID · 7a7957f0-1b31-4a96-ac86-698f4d0f2afe

Violation Codes10
21 CFR 21021 CFR 21121 CFR 211.100(a)21 CFR 211.110(a)21 CFR 211.22(a)21 CFR 211.19221 CFR 211.34FD&C Act 501(a)(2)(B)21 U.S.C. 356C(b)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Actavis Laboratories FL, Inc.
  • 483 - 2025-11-18November 18, 2025
  • EIR - 2021-05-25May 25, 2021
  • 483 - 2021-05-25May 25, 2021
  • 483 - 2020-01-17January 17, 2020
  • 483 - 2018-07-19July 19, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Actavis Laboratories FL, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.